Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 217

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Oncometabolites in renal cancer

Open access
Yong, Cissy, Stewart, Grant D., Frezza, Christian · 2020 · Nature Reviews Nephrology

Abstract

The study of cancer metabolism has evolved vastly beyond the remit of tumour proliferation and survival with the identification of the role of ‘oncometabolites’ in tumorigenesis. Simply defined, oncometabolites are conventional metabolites that, when aberrantly accumulated, have pro-oncogenic functions. Their discovery has led researchers to revisit the Warburg hypothesis, first postulated in the 1950s, of aberrant metabolism as an aetiological determinant of cancer. As such, the identification of oncometabolites and their utilization in diagnostics and prognostics, as novel therapeutic targets and as biomarkers of disease, are areas of considerable interest in oncology. To date, fumarate, succinate, l -2-hydroxyglutarate ( l -2-HG) and d -2-hydroxyglutarate ( d -2-HG) have been characterized as bona fide oncometabolites. Extensive metabolic reprogramming occurs during tumour initiation and progression in renal cell carcinoma (RCC) and three oncometabolites — fumarate, succinate and l -2-HG — have been implicated in this disease process. All of these oncometabolites inhibit a superfamily of enzymes known as α-ketoglutarate-dependent dioxygenases, leading to epigenetic dysregulation and induction of pseudohypoxic phenotypes, and also have specific pro-oncogenic capabilities. Oncometabolites could potentially be exploited for the development of novel targeted therapies and as biomarkers of disease. Oncometabolites — conventional metabolites that, when aberrantly accumulated, have pro-oncogenic capabilities — have been implicated in renal cell carcinoma (RCC). Here, the authors review the role of oncometabolites in RCC, their origins and downstream effects and their potential applications as novel therapeutic targets and biomarkers. Oncometabolites are aberrantly accumulated metabolites that possess pro-oncogenic capabilities, they contribute to tumorigenesis via epigenetic dysregulation and can influence tumour progression through phenotypic switches such as epithelial to mesenchymal transition. l -2-hydroxyglutarate, fumarate and succinate are bona fide renal cell carcinoma (RCC) oncometabolites; exploitation of these oncometabolites and their downstream signalling effects are attractive targets for novel therapies and as biomarkers of disease. Oncometabolites have shared pro-oncogenic functions owing to their ability to inhibit α-ketoglutarate-dependent dioxygenases as well as individual oncometabolite-specific functions. Chromatin remodelling via oncometabolites may recapitulate the effects of other epigenetic modifiers mutated in RCC, thus converging on the same gene signature; identification of the underlying pathways influences treatment strategy. Elucidation of exogenous factors that give rise to oncometabolite production, such as hyperglycaemia, may prove to be a synergistic strategy to reduce the levels of oncometabolites and their subsequent sequelae.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41581-019-0210-z

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 99 references

Cited by

See all 217

Metadata

Authors
Yong, C., Stewart, G. D., & Frezza, C.
Venue
Nature Reviews Nephrology
Published
2019-10-21
Volume
16
Issue
3
Pages
156-172
ISSN
  • 1745-8323 (ISSN-L)
  • 1759-5061
  • 1759-507X
OpenAlex
W2980329836
Cited by
217
References
99
FWCI
2.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oncometabolites in renal cancer. https://app.cochat.ai/papers/10.1038/s41581-019-0210-z
The paper
Yong, C., Stewart, G. D., & Frezza, C. (2020). Oncometabolites in renal cancer. Nature Reviews Nephrology. https://doi.org/10.1038/s41581-019-0210-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.